Patented Pharmacogenomic Technology · Switzerland

Your Genes Know Which Medications Are Safe for You.

MedGenie connects your unique genetic profile to every medication you take — delivering personalised safety information before adverse reactions occur.

Personalised Drug Safety Report
Warfarin 5mg
Anticoagulant · CYP2C9 · VKORC1
⚠ High Risk — Slow Metaboliser
↓ Recommended Dose: 2.5mg
95%
of people carry a gene variant affecting drug response
7M+
preventable adverse drug reactions annually in Europe
197K
Patients die from preventable adverse drug reactions every year in the EU
$136B
Annual cost of drug-related problems in the United States alone
1 in 5
Patients experience an adverse drug event that could be predicted by genetics
200+
FDA-approved drugs carry pharmacogenomic dosing guidance on their labels

One-size-fits-all medicine is costing lives.

Every person metabolises medications differently due to their genetic makeup. The same drug at the same dose can be safe for one patient — and life-threatening for another.

Yet today, most patients receive generic prescriptions with no consideration of their individual genetic profile. The result: preventable adverse reactions, hospitalisations, and deaths that could be avoided with personalised information.

Genetic Impact on Drug Metabolism
CYP2D6 (30+ medications)~7% poor metabolisers
CYP2C9 (Warfarin, NSAIDs)~8% reduced function
CYP2C19 (Clopidogrel, PPIs)~2% poor metabolisers
TPMT (Thiopurines / cancer)~10% reduced function
Adverse drug reactions are the 4th–6th leading cause of death in the US

Personalised safety in three steps.

MedGenie combines genetic data with real-time medication information to deliver actionable, personalised guidance at the point of care.

🧬

Genetic Profile

The patient's pharmacogenomic profile is securely stored — capturing the key gene variants that determine how their body processes medications.

📷

Scan Any Barcode

Using the mymedgenie app, scan any medication barcode (US, Swiss, or European). MedGenie instantly retrieves the official drug label from FDA, Swissmedic, or EMA.

Personalised Safety Report

Within seconds, the patient receives a personalised safety report — specific interactions, dosage adjustments, and risks based on their individual genetic profile.

Pharmacogenomics meets real-world medication data.

MedGenie's patented system bridges the gap between a patient's DNA and the medications they take — in real time, at scale.

🔬

Pharmacogenomic Engine

Integrates with genetic test results to interpret CYP450 enzyme activity, drug transporter variants, and receptor polymorphisms — covering 100+ clinically actionable gene-drug pairs.

🏷

Innovative Medication Labelling

Our patented labelling approach translates complex pharmacogenomic interactions into clear, patient-friendly safety information — replacing technical jargon with actionable guidance.

🔒

Secure Personal Health Data

Patients control their own genomic data. MedGenie is architected for full data sovereignty — no genomic data is shared without explicit patient consent.

🌍

Global Database Integration

Connected to FDA, Swissmedic, and EMA drug label databases via GS1 barcode standards — covering medications from the US, Switzerland, and across Europe.

Genetic Metabolism Profile
CYP2D6 Intermediate Metaboliser
Affects: Codeine, Tamoxifen, Antidepressants
CYP2C9 Normal Metaboliser
Affects: Warfarin, Ibuprofen, Diclofenac
CYP2C19 Poor Metaboliser
Affects: Clopidogrel, Omeprazole, SSRIs
Drug-Gene Interactions Found
4 across your current medications

Scan. Know. Stay Safe.

The mymedgenie patient app puts personalised medication safety in your pocket. Scan any medication barcode from the US, Switzerland, or Europe and receive your personalised safety report instantly.

Scan US, Swiss (Swissmedic), and European (EMA/FMD) barcodes
FDA drug label data — indications, dosage, warnings, interactions
Clinical drug-drug interaction checking via NLM RxNav
Works offline — scanned drugs cached on your device
Installs directly to your phone — no app store required
Request Early Access
mymedgenie
📷
SCAN MEDICATION BARCODE
Metoprolol 50mg
Beta-blocker · FDA Label · Swissmedic
CYP2D6 2 Interactions ⚠ Caution
My Medications (3)
Aspirin 100mg
Lisinopril 10mg
Metoprolol 50mg

Built for patients, providers, and partners.

Know your medications like never before.

For the first time, patients can understand exactly how their body will respond to any medication — before taking it. MedGenie translates complex pharmacogenomic science into plain-language guidance you can act on.

Know which medications match your genetic profile
Get alerts for dangerous drug-drug interactions
Maintain control over your personal health data
Works with medications from any country — US, Switzerland, EU
Request Early Access
😊
Medication Adherence
+34% improvement with personalised guidance
🛡
Adverse Reactions Prevented
Predictable in 95% of pharmacogenomic cases
📱
App Availability
iOS & Android · No app store required
🔒
Data Privacy
Patient-controlled · GDPR compliant

Better prescribing decisions, less risk.

MedGenie gives clinicians and pharmacists an evidence-based, patient-specific layer of safety information — integrated into the medication workflow to reduce adverse events and improve outcomes.

Gene-drug interaction alerts at the point of prescribing
Personalised dosing recommendations based on CPIC guidelines
Reduce adverse drug event liability and hospitalisation rates
Empowers patients — improving adherence and trust
Book a Clinical Demo
🏥
Readmissions Reduced
ADRs account for 5–8% of all hospital admissions
📋
Clinical Guidelines
Aligned with CPIC, DPWG pharmacogenomic guidelines
🔗
Integration
API-ready · EHR compatible · GS1 barcode standard
📊
Database Coverage
FDA · Swissmedic · EMA — 100+ gene-drug pairs

A patented platform in a $10B+ market.

The global pharmacogenomics market is growing at 11% CAGR, driven by precision medicine mandates, falling genetic test costs, and regulatory push for personalised drug labelling.

Granted US patent — proprietary pharmacogenomic labelling system
Multiple revenue streams: B2C app, B2B pharma API, hospital integration
Swiss holding structure — Bottmingen, Switzerland
Scalable SaaS model — works across any medication barcode globally
Request Investor Deck
📈
Market Size
$10.1B pharmacogenomics market by 2028
Growth Rate
11.5% CAGR — precision medicine mandates driving adoption
🛡
IP Protection
Granted US Patent · Trademark registered (IR 1914213)
🌍
Addressable Market
Global — US, EU, Switzerland, Asia-Pacific

Proprietary technology, protected globally.

MedGenie's pharmacogenomic medication labelling system is protected by a granted US patent — providing a durable competitive moat in the personalised medicine space.

🇺🇸
US Patent — Granted Pharmacogenomic medication labelling and patient safety system
Trademark IR 1914213 MEDGENIE + Logo — internationally registered
🇨🇭
MedGenie AG — Switzerland Incorporated in Bottmingen, Switzerland
🏛
Pharmacogenomic Medication Management & Safety Labelling
United States Patent — Granted
Patent Holder MedGenie AG
Jurisdiction United States
Status ✓ Granted
Trademark IR 1914213

Bridging genomics and everyday medicine.

MedGenie AG is a Swiss health technology company founded on the belief that every patient deserves medication safety information tailored to their unique genetic profile.

🎯

Our Mission

To eliminate preventable adverse drug reactions through personalised pharmacogenomic guidance — making precision medicine accessible to every patient, everywhere.

💡

Our Innovation

We invented a novel system that integrates individual genomic profiles with real-time drug label data and innovative safety labelling — protected by a granted US patent.

🇨🇭

Swiss Excellence

Headquartered in Bottmingen, Switzerland — we combine Swiss precision and reliability with a global vision for personalised healthcare.

MF
Dr. Michael Forstner
CEO & Chief Medical Officer
Physician and medical innovator leading MedGenie's clinical strategy and vision. Pioneered the pharmacogenomic labelling system protected by US patent.
🇨🇭 Switzerland MedGenie AG
AE
Dr. Andrew Ertl
Chief Operating Officer
Leads operations, strategy, and partnerships at MedGenie AG. Driving the commercialisation of patented pharmacogenomic technology to improve patient safety globally.
🇨🇭 Bottmingen, Switzerland MedGenie AG

Let's talk.

Whether you're a patient seeking early access, a healthcare provider interested in a demo, or an investor exploring partnership opportunities — we'd love to hear from you.

👤
CEO & Chief Medical Officer
Dr. Michael Forstner
👤
Chief Operating Officer
Dr. Andrew Ertl
🇨🇭
Headquarters
MedGenie AG, Bottmingen, Switzerland
✉️
Email
info@medgenie.ch
🌐
Website
medgenie.ch
✅ Thank you — we'll be in touch within 48 hours.